Biogen Idec (BIIB) Says AVONEX More Cost Effective to Other Interferon Therapies for Multiple Sclerosis
More News related to BIIB
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
More News related to Corporate News
- S&P Announces Changes to US Index: CMN for NTG, CVGW for STSA
- Kinross (KGC) Enters Agreement for $125M Letter of Credit Facility
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
Biogen Idec Inc. (NASDAQ: BIIB) announced that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments.
Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.
Related Categories
Corporate NewsStocks Mentioned
+0.92Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
